Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 253968
IPSCIO Record ID: 336295
Licensee, at Universitys request, shall grant to a third party a royalty bearing, sublicense under Patent Rights in the field defined by Licensee and the third party. Licensee shall be required to grant only one sublicense under this Agreement.
Inventions shall mean new and useful improvements in the construction of Papillomavius hybrid particles conceived and reduced to practice by all employees of University, and disclosed to University in University Invention Disclosure dated September 28, 1994, and December 16, 1996, and as amended from time to time.
IPSCIO Record ID: 319599
Licensor hereby grants to Licensee the exclusive option to enter into a license agreement from Licensor for the commercial development, use, and sale of the Technology, products based on the Technology, patents, trade secrets, know-how, and other information related to the Technology;
Materials shall mean the materials and/or intellectual property listed
– Licensor IDF Number 2013-2417 entitled â€œNon-Covalent Loading of Plant Picornavirus Particlesâ€ with US Patent Application US2015/0376578 A1 and EP Patent Application 14754692.3
– Licensor IDF Number 2015-2767 entitled â€œCancer Immunotherapy using Virus Particles with US Patent Application US2018/0133304 A1 and associated foreign patent applications in Japan, China, Canada, Australia, and EP, US non-published patent application with patent serial number 16/612,214, and PCT Patent application with publication number WO 2018/208828 A1
– Licensor IDF Number 2017-3151 entitled â€œMelt Processed Viral Nanoparticle Constructsâ€ with US Patent Application US2019/0350871 A1 and EP Patent Application 17868454.4
Patents shall mean any patent that issues or has issued to Licensor or patent application covering or consisting of the Technology and based on intellectual property in existence as of the Effective Date and any related patent or patent application that is a continuation, continuation-in-part, divisional, or reissue in the United States of America or any other country.
The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19.
The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.
This immuno-oncology approach provides a personalized treatment approach by relieving the patientâ€™s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor.
The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.
Field of Use shall mean all therapeutic, diagnostic, vaccine and preventive uses of Technology for both veterinary and human applications. Final field of use, including specific indications, which may be narrower than the Field of Use, will be defined in any commercial use license. Said commercial use license will necessarily incorporate developmental, regulatory, and commercial distribution/sales milestones for each product that incorporates any Technology in the Field of Use. For clarification purposes, Technology and Materials shall not be used in or on humans during the Evaluation Period unless Licensee consults with Licensor regarding appropriate, and possibly expanded, indemnification and insurance requirements and receives Licensorâ€™s written authorization to do so. Such authorization will be in Licensorâ€™s sole discretion.
IPSCIO Record ID: 6938
Sublicensing – Upon written approval by Licensor, which approval will not be unreasonably withheld, Licensee may enter into sublicensing agreements under the Licensed Patent Rights.
Licensed Fields of Use – Exclusive. Licensed Territory – Worldwide.
Serial Number(s) of Licensed Patent(s) and/or Patent Application(s) U.S. Patent No. 6,387,662 (U.S. S/N 09/246,441), issued May 14, 2002, entitled 'Synthesis and Purification of Hepatitis C Virus-Like particles' (E-009-1997/0) (Inventors T. Jake Liang
(NIDDK), Thomas F. Baumert (NIDDK)). This application is a continuation of and claims the benefit of priority of International Application No. PCT/US97/05096
designating the U.S. having International filing date of Mar. 25, 1997, abandoned, claims the benefit of priority of U.S. S/N 60/030,238, filed Nov. 8, 1996.
PCT/US97/05096 filed March 25, 1997, entitled 'Synthesis and Purification of Hepatitis C Virus-Like particles in vitro' (related to E-009-1997/0) (Inventors T. Jake Liang (NIDDK), Thomas F. Baumert (NIDDK)). National Stage filed March 25, 1997 in Australia Patent No. 738585, issued Jan. 03, 2002, in EPO patent application No. 9791652.6, in Canada patent application No. 2269097, in Japan patent application No. 10-522521.
IPSCIO Record ID: 364016
Licensor also hereby grants to Licensee an exclusive license to make, use, and/or sell the Licensed Materials in the Territory for the Field of Use. At Licensees request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.
U.S. patent application serial number US 61/033,425 entitled 'Heat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 20 March 2008;
PCT patent application number PCT/US2009/001727 entitled 'bleat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 19 March 2009;
all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT patent application number PCT/US2009/001727 to meet the requirements of 35 U.S.C. 112Â¶1; and any re-examinations or reissues of the foregoing.
â€œPatent Rightsâ€ shall mean the following United States Patent applications U.S. patent application serial number US 61/033,425 entitled â€œ Allogeneic Cancer Cell-Based Immunotherapyâ€ and files on 3 March 2008; PCT patent application number PCT/US2009/001330 entitled â€œAllogeneic Cancer Cell-based Immunotherapyâ€ and filed on 3 March 2009; all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT application number PCT/US2009/001330 to meet the requirements of 35 U.S.C. 112Â¶1; and any re-examination or reissues of the foregoing.
IPSCIO Record ID: 26212